Okanvision Bio-B (01477) announced OT, the first novel drug of its kind developed by the company to treat dry eye syndrome...
Zhitong Finance App News, Okanvision Bio-B (01477) announced that a phase II clinical trial of OT-202 (tyrosine kinase inhibitor), the first novel drug of its kind developed by the company to treat dry eye, has been successfully revealed, and all relevant data have been collected. This indicates that OT-202 has reached the main clinical end point of the phase II clinical trial, that is, the 56th day corneal staining score of the treatment group treated with this drug is better than the placebo group. The drug has shown positive results in terms of safety and efficacy. The company expects to commence phase III clinical trials of OT-202 in the near future.
According to reports, OT-202 (tyrosine kinase inhibitor) is the first novel drug of its kind developed by the company to treat moderate to severe dry eye conditions. The mechanism of action of OT-202 is an inhibitor with spleen tyrosine kinase (Syk) and vascular endothelial growth factor receptor 2 as dual targets. It has a synergistic effect in treating dry eye and suppresses inflammatory response. In a phase I clinical trial successfully completed in February 2023, OT-202 showed good safety and tolerability in healthy adult subjects. The phase II clinical trial of OT-202 (started in February 2023 and is planned to be a randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of the drug). A total of 213 patients were enrolled in the phase II clinical trial in China in November 2023.